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Abstract
Background: Despite a resurgence in control efforts, malaria remains a serious public-health problem, causing
millions of deaths each year. One factor that complicates malaria-control efforts is clinical immunity, the acquired
immune response that protects individuals from symptoms despite the presence of parasites. Clinical immunity
protects individuals against disease, but its effects at the population level are complex. It has been previously
suggested that under certain circumstances, malaria is bistable: it can persist, if established, in areas where it would
not be able to invade. This phenomenon has important implications for control: in areas where malaria is bistable, if
malaria could be eliminated until immunity wanes, it would not be able to re-invade.
Methods: Here, we formulate an analytically tractable, dynamical model of malaria transmission to explore the
possibility that clinical immunity can lead to bistable malaria dynamics. We summarize what is known and unknown
about the parameters underlying this simple model, and solve the model to find a criterion that determines under
which conditions we expect bistability to occur.
Results: We show that bistability can only occur when clinically immune individuals are more “effective” at
transmitting malaria than naïve individuals are. We show how this “effectiveness” includes susceptibility, ability to
transmit, and duration of infectiousness. We also show that the amount of extra effectiveness necessary depends on
the ratio between the duration of infectiousness and the time scale at which immunity is lost. Thus, if the duration of
immunity is long, even a small amount of extra transmission effectiveness by clinically immune individuals could lead
to bistability.
Conclusions: We demonstrate a simple, plausible mechanism by which clinical immunity may be causing bistability
in human malaria transmission. We suggest that simple summary parameters – in particular, the relative transmission
effectiveness of clinically immune individuals and the time scale at which clinical immunity is lost – are key to
determining where and whether bistability is happening. We hope these findings will guide future efforts to measure
transmission parameters and to guide malaria control efforts.
Background
Despite extensive efforts to eradicate it, malaria caused
by Plasmodium falciparum remains a significant prob-
lem resulting in millions of cases and 660,000 deaths in
2010 [1]. A characteristic of falciparum malaria disease
that complicates control efforts is clinical immunity – an
immune response that develops with exposure to parasites
and provides protection against the clinical symptoms of
malaria, despite the presence of parasites [2]. Although
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clinical immunity protects individuals against disease, its
effects at the population level are complex.
Malaria is highly variable from region to region, fur-
ther complicating analysis. Geographic variation in aver-
age disease burden (endemicity) leads to variation in
acquired immunity [3]. Malaria endemicity ranges from
“holoendemic” (defined as having a parasite ratio (PR, the
percentage of subjects with parasites found in the blood)
consistently greater than 75% of infants [4]) through
“hyperendemic” and “mesoendemic” to “hypoendemic”,
defined as having a PR of less than 10% of children age
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2–9 [4]. This results in variation in the acquisition of clin-
ical immunity. This variation in endemicity and clinical
immunity complicates malaria epidemiology and control.
Clinical immunity to malaria develops after exposure to
parasites and varies as endemicity varies [5,6]. In holoen-
demic regions, exposure to parasitemia is high enough
that clinical immunity develops rapidly, and most adults
and older children are clinically immune, whereas in
hypoendemic regions, most people are not re-infected
often enough to develop clinical immunity [6]. Even after
it develops, clinical immunity can be lost in 3-5 years with-
out re-exposure [2,3,5-7]. When individuals first develop
clinical immunity, they are only immune to severe symp-
toms. If re-exposure continues, however, clinical immu-
nity can result in asymptomatic or nearly asymptomatic
disease. Full clinical immunity develops slowly and tends
to correlate with the onset of puberty [6,8].
An important aspect of clinical immunity is the possi-
bility that clinically immune individuals are particularly
effective at transmitting malaria over the duration of
their infections. This phenomenon could arise if clinically
immune individuals are more infectious to mosquitoes
per unit time, or if they stay infectious for longer (perhaps
because they are less likely to seek medical treatment),
or both. If clinically immune individuals have a higher
reproductive rate, this has potential implications at the
population level – in some cases, malaria may be spread
more effectively in areas where it is already present, all else
being equal.
As transmission of malaria decreases, the proportion of
the population protected by clinical immunity decreases
as well, since clinical immunity is lost. As a result,
decreases in transmission can, under some circumstances,
lead to an increase in morbidity and mortality, because
fewer people are protected against the symptoms of
malaria [9-11].
Águas et al. [12] have shown that under certain cir-
cumstances when clinically immune individuals are more
infectious over the duration of their infection, than naïve
cases, malaria can persist, if established, in areas where
it would not be able to invade. In other words, for some
sets of parameters, both an endemic equilibrium and
a disease-free equilibrium are stable – a phenomenon
known as bistability. Bistability would have important
implications for malaria control: in particular, it would
imply that there are some areas where, if malaria could
be eliminated until clinical immunity wanes, it would not
be able to re-invade. Here we use a model of malaria
transmission to explore under which conditions we would
expect bistability to occur, indicating possible opportuni-
ties for malaria elimination.
Malaria elimination has been surprisingly effective in
many countries: 75 of the 79 countries that success-
fully eliminated malaria between 1945 and 2010 remain
malaria free, even thoughmany have not sustained control
efforts [13]. A recent paper by Chiyaka et al. [14] presents
six hypotheses for this phenomenon, and argues that R0
may be reduced either by external factors, like demo-
graphic and hydrological changes, or by factors driven by
malaria elimination itself, for example economic devel-
opment catalyzed by reduced disease burden, or bista-
bility due to treatment seeking. They argue that, to the
extent that malaria elimination reduces R0, incentives to
aggressively pursue control are increased, since on-going
active control efforts will not be required once malaria is
eliminated.
In this paper, we first review what is known about
infectiousness and susceptibility to infection of clinically
immune individuals. We then build a simple transmission
model designed to elucidate what factors make bistabil-
ity likely, and what measurements could shed light on
when and whether bistability is likely to be an impor-
tant phenomenon in malaria dynamics and control. We
derive a simple mathematical criterion for how “effective”
transmission by clinically immune individuals must be for
bistability to occur.
Effects of clinical immunity on disease transmission
The overall infectiousness of an infected individual is the
product of duration of infection, and mean infectious-
ness. Below, we review what is known about the effects of
clinical immunity on these components.
The duration of a malaria infection is highly variable,
and treatment-seeking behavior is an important deter-
minant. In a review of population-level studies done
on malaria treatment-seeking behavior, McCombie [15]
found that treatment rates were correlated with severity of
symptoms, and that in Africa, 64–95% of individuals who
sought treatment received at least one form of treatment;
with the majority of studies reviewed reporting over 90%
treatment rate.
It is well known that many clinically immune infec-
tions are not even recognized by the individual as malaria.
Individuals in hyper- and holo-endemic areas who do
not think they have malaria, have been found to test
positive at high rates, for example in Ghana [15,16],
Senegal [17], and Kenya [18]. Thus, it seems reasonable
to suppose that most clinically immune infections are
untreated, and last longer than treated clinical infections
because of treatment-seeking behavior. Various studies
have been done to estimate the duration of untreated
malaria infection. Earle et al. [19] observed the duration
of infection in children age 5-15 years old and found all
of them had cleared the infection within a year. How-
ever, most of what is known about duration of infection
comes from malariatherapy data. These studies infected
malaria-naïve syphilis patients with P. falciparum strains
with low clinical virulence and found the mean duration
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of infection to be 200 days [20]. A recent study in a highly
endemic region found a similarmean duration of infection
to that of the malariatherapy data, however, they found a
larger variance in duration of infection with many more
infections with shorter duration than found in the malar-
iatherapy data [21]. And in an extreme case, an infection
was found 8 years after last known exposure to parasites
[22]. However, it’s not clear how the duration of untreated
clinically immune infections compares to untreated symp-
tomatic cases. Bruce et al. [23] found that “episodes” of
parasitemia lasted longer in children than in adults and
suggest that this may be due to clinical immunity [23].
Unfortunately, it is not straightforward to relate their
measured episodes to infection clearance (partly because
infected individuals may be “super-infected” by other
strains).
While clinically immune cases are frequently asymp-
tomatic or of low clinical virulence, data from malar-
iatherapy studies suggest naïve cases may also have a
wide range of clinical virulence ranging from high vir-
ulence to asymptomatic [24]. Other studies suggest that
asymptomatic malaria is not limited to areas of high trans-
mission where exposure-related immunity is expected to
develop [25-27]. Thus, not all naïve cases may be termi-
nated with treatment.
Another key component to the population-level effects
of clinical immunity is the infectiousness per trans-
mission event of infected individuals. Although malaria
transmission is much studied, it remains unclear how
parasitemia, gametocytemia, and other factors inter-
act to affect malaria transmission. Gametocyte quantity
alone is not sufficient to ensure successful transmis-
sion; mosquito uptake of gametocytes depends on a wide
variety of factors, including transmission-blocking immu-
nity (TBI) [28-30] and cytokine tumor necrosis factor
(TNF) [31,32].
Transmission-blocking immunity (TBI) is a human
immune reaction to sexual stages of malaria. TBI devel-
ops with exposure to gametocytes and, through a variety
of mechanisms, reduces successful transmission of new
infections. TBI increases with gametocyte density; conse-
quently, TBI tends to be negatively correlated with clinical
immunity [30], but the importance of TBI to population-
level transmission is not clear. In one study, transmission-
blocking immunity was found to reduce transmission by
up to 90%, with higher immunity in the younger age
groups [30]. Two other studies, which did not include the
youngest age group, failed to find correlations between
age and TBI [33,34]; the latter of these found that only
15% of urban and 29% of rural gametocyte carriers had
reduced transmission. A model of human infectiousness
tomosquitoes found that patterns of EIR across Africa and
Papua New Guinea could be explained without invoking
TBI [35].
Cytokine TNF is another factor that affects gametocyte
success. It is present in the blood serum taken during
the crisis of a malaria infection [31,32]. Cytokine TNF is
responsible for the loss of infectiousness during peak par-
asitemia by killing the gametocytes. Gametocytes present
during malaria crisis were found dead before entering the
mosquito; as well, gametocytes from crisis serum failed to
infect mosquitoes even when washed and re-suspended in
normal serum [31].
Although there is immunity against gametocytes at
peak parasitemia in non-immune individuals, clinically
immune infections often have lower gametocytemia as a
result of having anti-parasite immunity, conferring pro-
tection against high-density parasitemia [7]. There is also
evidence that clinically immune individuals are less infec-
tious per bite, but because clinically immune individuals
are less likely to seek treatment, they are consistently
infectious at low levels for long periods of time and there-
fore result in producing a large number of new infections
over the course of a single clinically immune infectious
period [36,37].
As we will see below, susceptibility to infection in
clinically immune individuals is also important to the
population-level dynamics of malaria. Although a great
deal is known about susceptibility to clinical illness, par-
asitemia or gametocytemia [38,39], much less is known
about susceptibility to new infection. Individual suscep-
tibility to new infections is complex, and known to be
influenced by genotype, parasite virulence, and specific
immunity [38], but there is evidence to believe that clin-
ically immune individuals are about as susceptible to
disease as non-immune individuals [40].
Population-level effects
We investigate the factors underlying bistability with
a simple transmission model that accounts for clinical
immunity (see Methods). We assume that individuals
infected when they are naïve have a probability of becom-
ing clinically immune when they recover from infection,
and that clinically immune susceptible individuals lose
immunity at some rate if not infected again, meaning
that clinical immunity will be maintained when the force
of infection is high, and will often wane if the force of
infection is low.
To explore the effects that clinically immune individuals
have on the population-level disease dynamics, we com-
pare the life-cycle transmission effectiveness of naïve and
clinically immune individuals, using subgroup reproduc-
tive numbers. These are defined as the average number
of secondary infections from a single infectious individual
in an otherwise totally susceptible population. We define
the reproductive number for naïve cases, RNN , as the
average number of secondary infections generated by a
single naïvely infectious individual in an otherwise totally
Keegan and Dushoff BMC Infectious Diseases 2013, 13:428 Page 4 of 11
http://www.biomedcentral.com/1471-2334/13/428
naïvely susceptible population. We define the reproduc-
tive number for clinically immune cases, RCC , as the
average number of secondary infections given by a sin-
gle clinically immune infectious individual in an otherwise
totally clinically immune population.
Because we assume that all individuals are naïve in the
absence of infection, the basic reproductive number of
our system R0 = RNN . We stress that this is the basic
reproductive number in the presence of baseline control
efforts – in particular, we assume that treatment is always
available to those who seek it. This R0 will typically dif-
fer from theR0 that would be calculated in the absence of
control [14].
The reproductive numbers determine malaria disease
dynamics. When RNN > 1 the disease will always per-
sist. WhenRNN ≤ 1 the disease cannot invade. However,
there is evidence that under certain circumstances when
RCC > 1 > RNN , clinically immune individuals can
act as a reservoir and allow malaria to remain endemic,
even thoughRNN drops below one. In this case, both the
disease-free equilibrium and an endemic equilibrium are
stable, this is an example of “bistability”.
Bistability is typically associated with “backwards bifur-
cations”. In general, as a disease invades, it reduces its
reproductive number R, primarily by reducing the num-
ber of susceptibles in the population. In such “forward
bifurcations”, we expect the disease to go extinct from any
starting conditions when R0 ≤ 1, and to reach a small
equilibrium, whenR0 is just above 1 [41]. When a disease
increases its reproductive number as it invades, backwards
bifurcations occur. In a backwards bifurcation, the disease
invades to a non-zero level even whenR0 = 1, and will be
able to persist above a certain threshold when R0 is just
below 1 [41].
Methods
To explore the dynamics of malaria and determine the
conditions in which bistability can occur, we evaluated the
following simple transmission model (Figure 1):
dSN
dt = −SN + αSC − μSN + μT + γNNIN (1a)
dIN
dt = SN − (γNN + γNC)IN − μIN (1b)
dSC
dt = −σSC − αSC + γNCIN + γ CIC − μSC (1c)
dIC
dt = σSC − γ CIC − μIC (1d)
SN represents naïve susceptible individuals: individu-
als who have never been infected with malaria, those
who have been infected but have not developed clinical
immunity, or who have lost all immunity. When infected
with malaria, they move to the clinically infected class
Figure 1 Compartmental diagram of our malaria transmission
model. Each compartment in the diagram represents a different
epidemiological class. Individuals begin in the susceptible naïve class
(SN), return there after losing clinical immunity, at a rate α, and are
born into this class, at a rate μ. Individuals in SN who get infected
move to the infected naïve class (IN), at a rate . From IN , individuals
recover from illness to either the susceptible naïve class (SN), at a rate
γNN , if immunity was not conferred, or to the susceptible clinically
immune class (SC ), at a rate γNC if clinical immunity developed.
Individuals who are susceptible clinically immune can either lose
immunity at a rate α and return to the susceptible naïve class, or they
can get infected, at a rate σ, and become infected clinically immune
(IC ). Infected clinically immune individuals recover to the susceptible
clinically immune class, at a rate γC . Individuals can die from any of
the epidemiological classes and do so at a rate μ independent of the
level of malaria in the population. Individuals are born and die at the
same rate, thus keeping the population size constant.
(IN ). Recovered individuals become immediately suscep-
tible again, but with immunity to clinical symptoms (SC).
When non-naïve susceptibles get infected, they acquire
clinically immune infections (IC). Each class represents a
portion of the population. τN and τC are the transmission
rates of naïve and clinically immune cases, respectively.
γNN is the rate at which naïve individuals recover with-
out clinical immunity, γNC is the rate they recover with
clinical immunity, and γC is the recovery rate for clinically
immune individuals. α is the rate at which clinical immu-
nity is lost σ is the relative susceptibility to new infection
of clinically immune individuals.  = τN IN+τCICT is the
force of infection. Both types of susceptibles (naïve or clin-
ically immune) can be infected by either type of infectious
individual (naïve or clinically immune). The total popu-
lation size is T = SN + IN + SC + IC . For this model,
R0 = RNN = τNγNN+γNC+μ , andRCC =
στC
γC+μ . We define ρto be the ratio of the clinically immune reproductive num-
ber to the naïve reproductive number (RCC/RNN ). And
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π = γNC
γNN+γNC is the proportion of naïve infections thatrecover to become clinically immune.
We used the statistical package R [42] to simulate our
model.We held the average durations of infectiousness for
naïve and immune individuals (1/γNN and 1/γC) constant
at 50 and 200 days respectively. We chose π = γNC
γNC+γNNto be 0.5, assuming an equal chance of getting clinical
immunity and remaining non-immune after each naïve
infection; results with π = 1 were similar. Transmission
coefficients τN and τC were calculated from RNN and
RCN which varied as described in the Results section. We
chose duration of immunity 1/α to be 1282 days (about 3.5
years), and lifespan 1/μ to be 25,550 days (about 70 years).
The relative susceptibility of clinically immune individuals
was chosen to be σ = 0.7 since clinically immune individ-
uals are about as susceptible as naïve cases; we also tested
other values.
R code and Maxima code to replicate all of our results
will be made available upon publication.
In building a simple transmission model, we have
lumped a variety of biological mechanisms into the
parameters. For example, transmission parameters τC
and τN include transmission blocking immunity and the
reduction of parasites in clinically immune individuals.
The duration of infection parameters γNN , γNC , and γC
take into account treatment seeking behavior (naïve indi-
viduals are likely to seek treatment quickly whereas clini-
cally immune individuals are less likely to seek treatment
or they wait longer to seek treatment).
Results
We simulated our malaria transmission model under two
scenarios of infectiousness: overall infectiousness of clini-
cally immune cases was either low (ρ ≡ RCC/RNN = 0.8,
panels 2a and 2b) or high (ρ = 4, panels 2c and 2d).
For each scenario, we simulated two different values
of R0 ≡ RNN . Disease-invasion results are shown in
Figure 2.When we start near the disease-free equilibrium,
the qualitative behavior is determined byR0: whenR0 >
1 (panels 2a and 2c), the disease invades and reaches an
endemic equilibrium; when R0 < 1, (panels 2b and 2d),
the disease does not invade.
In the case where underlying parameters can change
over time, however, there are striking differences between
the scenarios with low and high relative transmission from
immune individuals. Figure 3 shows what would happen
in a population with endemic malaria if control efforts
moved transmission from the first column of Figure 2
to those shown in the second column. Panel 3a behaves
as we would expect: when we change the parameters at
day 3000, the system moves to the disease-free equilib-
rium. Panel 3b, however, exhibits bistability. Although
the parameters in the latter part of the simulation are
consistent with disease extinction, the disease does not
go extinct from the equilibrium reached under high
transmission, but instead finds a lower endemic equilib-
rium. Whether or not malaria will remain endemic or die
out under parameters consistent with disease extinction is
dependent both onR0 and on initial conditions.
Figure 4 gives a broader perspective on the two sce-
narios, using “bifurcation diagrams” showing how equi-
librium incidence changes as R0 increases, while holding
the relative infectiousness of clinically immune individ-
uals (ρ ≡ RCC/RNN ) constant. Panel 4a illustrates the
scenario where clinically immune individuals are relatively
less effective at transmitting disease (ρ < 1). Here we
see the simple, common, relationship between R0 and
equilibrium incidence. AsR0 increases past 1, the system
moves smoothly from having a globally stable equilibrium
at 0, to having a globally stable endemic equilibrium.
Panel 4b shows shows the scenario where clinically
immune individuals are relatively more effective at
transmitting disease (ρ > 1). In this case, we see a more
complicated pattern, where both R0 and initial preva-
lence affect the final outcome. In particular, if we in-
crease R0 smoothly past 1 in a population where the
disease is absent, the equilibrium jumps abruptly; if the
disease invades, andR0 is decreased back below 1 the dis-
ease does not necessarily go extinct. Similarly, if Rcrit <
R0 < 1 (the light gray region of the plot), a tempo-
rary intervention that sharply reduces disease prevalence
could succeed in eliminating the disease even without a
long-term reduction inR0.
To be specific, we don’t expect the disease to go extinct
once established unless R0 is reduced beneath the mini-
mum value for which the endemic equilibrium exists. We
call this value Rcrit and the force of infection  that cor-
responds to it crit . On the forward bifurcation diagram
(Figure 4a) Rcrit = 1 and on the backwards bifurcation
diagram (Figure 4b) Rcrit is precisely the point where the
stability of the endemic equilibrium (in a region of bista-
bility) changes from unstable to stable (the black dot on
Figure 4b).
In Additional file 1, we show that a backwards bifur-
cation will occur when the ratio ρ∗ = RCC/RNN > ρ,
where:
ρ∗ = 1 + D
πL (2)
Here L = 1/(α + μ) is the duration of immunity,
D = 1/(γNC + γNN ) is the duration of naïve infec-
tion, and π = γNC
γNC+γNN is the proportion of peoplewho become clinically immune after a naïve infection.
This criterion determines for what parameters bista-
bility can occur when R0 < 1. The value of ρ∗ is
always strictly greater than 1, meaning that bistability
only occurs when RCC exceeds RNN by a sufficient
amount. The amount of excess necessary is determined
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Figure 2 Simulation of malaria transmission in a naïve population.We simulated malaria transmission in a population with 95% naïve
susceptible and 5% naïve infectious individuals (SN = 0.95, IN = 0.05, SC = 0, IC = 0,N = 1, α = 0.001, γNN = 0.02, γNC = 0.02, γC = 0.005,
μ = 0.000039, and σ = 0.7) under two assumptions of ρ . Panels a and b show ρ = 0.5 and panels c and d show ρ = 3.5
(a)RNN = 2 > 1 > RCC = 1. (b) 1 > RNN = 0.75 > RCC > 0.375. (c)RCC = 7 > RNN = 2 > 1. (d)RCC = 2.625 > 1 > RNN = 0.75.
by how quickly immunity is lost (through death or wan-
ing) compared to the duration of infectiousness of the
disease: when immunity lasts longer, bistability is more
likely.
When ρ > ρ∗, a backwards bifurcation occurs, resulting
in a region of bistability where there exists a stable disease-
free equilibrium and a stable endemic equilibrium for
the same parameter values. Figure 4b illustrates the back-
wards bifurcation and the region of bistability (light gray
shaded region). Within the region of bistability, if malaria
were to be eliminated, it would not be able to re-invade
unlessR0 were increased from below one back above one,
making malaria elimination from these regions more sus-
tainable. In order to eliminate malaria from a region of
bistability, either the force of infection must be reduced
below the unstable endemic equilibrium (dashed curve),
or the reproductive number must be reduced below
the critical value (Rcrit), or a combination of these. In
Figure 4b, this is equivalent to leaving the light gray shaded
region (without exceedingR0 = 1, the dashed line).
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Figure 3 Simulation of malaria transmission model with control.Malaria transmission with changing parameters. Here we simulated malaria
using the parameters from the first column of Figure 2 until they reached equilibrium at which point we changed the parameters to those in the
second column and allowed malaria to reach equilibrium again. (a)We used the parameters from Figure 2a from 0 to 3000 and the parameters
from Figure 2b from 3000 to 6000. (b)We used the parameters from Figure 2c from 0 to 3000 and from Figure 2d from 3000 to 6000.
We explored how different model parameters affected
the bifurcation diagram (Figure 5), by varying each param-
eter individually. To varyR0, we changed τN and τC , while
keeping their ratio constant. To vary ρ or to adjust ρ when
necessary (e.g., when changing σ ), we varied the ratio
τN : τC .
We show that the region of bistability depends strongly
on the ratio ρ. When ρ is large, bistability can occur
even for large incidence rates, as shown in Figure 5.
Consequently, if malaria were to be eliminated then re-
introduced, it would jump to being endemic at a higher
level in the population than when ρ is small. When ρ is
large, crit (the value of  that corresponds to Rcrit) is
also large. A large value of crit means that the force of
infection needs to be reduced by less to move below the
unstable endemic equilibrium and be eliminated.
We also found that even when ρ is held constant, the
individual components of ρ (σ , π and γC) still affect
the bifurcation diagram, as shown in Figure 5. When we
increased σ (Figure 5) while holding ρ constant, the region
of bistabililty decreased. When σ is small (Figure 5) the
proportion of infections that occur in clinically immune
people increases, thus increasing the accumulation of clin-
ical immunity and magnifying its effect on transmission.














Figure 4 Bifurcation diagram for our model. Bifurcation diagram for malaria. The dashed line showsR0 = 1 and the arrows show the behavior
of the system: in the white area, to the left of the manifold, the disease will die out while to the right of the manifold, in the shaded area, the disease
will persist. The dark-shaded region represents the area in which malaria can invade and persist and the light-shaded area in which it persists, even
though it would not invade. In these figures, all parameters are held constant except τN and τC . (a) A forward bifurcation occurs atR0 = 1. ρ = 0.8.
(b) A backwards bifurcation occurs atR0 = 1. ρ = 4.
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Figure 5 Bifurcation diagrams changing model parameters individually (ρ, σ , π , and γC ) while keeping all other parameters constant at
the base model values (Figure 4b). The vertical dashed line showsR0 = 1; the solid curve represents the stable equilibrium and the dotted curve
shows the unstable equilibrium; the point shows (Rcrit ,crit); the light grey area shows the region of bistability– the area where malaria will persist,
if endemic, but cannot invade; and the dark grey region shows where malaria can always invade and persist. In all of the bifurcation diagrams,R0
ranged from 0 to 1.5 andRCC varied accordingly, changing only transmission rates (τN and τC ). (a)-(c) vary ρ (a) The ratioRCC : RNN is 1 : 2 (b) The
ratioRCC : RNN is 2 : 1 (c) The ratioRCC : RNN is 4 : 1. (d)-(f) vary σ (d) σ = 0.5, (e) σ = 0.7. (f) σ = 1. (g)-(i) vary π while keeping γNC constant
(g) π = 0.66 (h) π = 0.5 (i) π = 0.33 (j)-(l) vary γC (j) clinically immune infections clear in 100 days (k) clinically immune infections clear in 200
days (l) clinically immune infections clear in 400 days.
We also explored the dynamics when varying the recov-
ery rates (Figure 5), while holding ρ constant. When indi-
viduals recover quickly, the area of bistability is large, since
there are more susceptible clinically immune individuals
in the population. When γC is large, crit is also large;
this means that the force of infection needs to be reduced
by less to drop below the unstable endemic equilibrium
for malaria to be eliminated. Also, when γC is large, the
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value of  when R0 = 1 is larger than when individuals
recover slowly. So if malaria is eliminated then re-invades,
it would jump to a high endemic level in the population.
A study of malaria resurgence found many cases where
incidence jumped to a high endemic level from low (or
undetectable) levels [43]. We also change the proportion
of naïve infections, π . When π is large, so isRcrit andcrit
and as π is decreased, so is Rcrit and crit , making the
region of bistability larger.
Discussion
The question of whether there are places where malaria
is endemic, but where it could remain stably eliminated
under current transmission and treatment conditions (ie.,
places where malaria is bistable) is important to inter-
preting malaria data and planning control measures. It
has been suggested that treatment-seeking behavior can
lead to bistability in the dynamics of malaria infections of
humans [12].
In areas where malaria is bistable, an aggressive pro-
gram that held malaria infection at low levels until clinical
immunity wanes could result in the disease remaining
absent even after the program is terminated. Malaria
would not re-invade in this case because treatment
seeking by non-immune infected individuals would lead
to shorter duration of infectiousness and less overall
transmission. This is a potentially risky strategy, how-
ever, because if malaria does re-invade such an area,
the fact that clinical immunity has waned could lead
to increased morbidity [9-11]. Mass drug administra-
tion (MDA) is a possible example of such an aggressive
approach. Although MDA has so far proved unsuccess-
ful in permanently interrupting malaria transmission, it is
successful at reducing parasitemia and does temporarily
reduce transmission [44]. Further investigation of factors
underlying bistability could improve understanding of
when andwhereMDAwould be likely to lead to long-term
elimination.
We analyzed a simple model, and found a simple cri-
terion that determines whether bistability can occur. In
particular, we found that the key quantity is the life-cycle
“transmission effectiveness” of clinically immune individ-
uals, relative to non-immune individuals. We encapsulate
this relative infectiousness in a ratio, which we call ρ
and show that bistability can occur when ρ exceeds
1 + D/(πL), where D is the duration of naïve infec-
tion, π is the proportion of naïve cases that recover
to become clinically immune, and L is the length of
immunity. We also show that, in addition to duration
of infection and ability to transmit the disease, the
relative susceptibility of clinically immune individuals
to new infections is a key component of this ratio.
Although the relative susceptibility is a key component
to understanding bistability in malaria, little is known
about the relative susceptibility of clinically immune
individuals.
Chiyaka et al. [14] discuss the importance of reduc-
ing the reproductive number under control efforts (RC)
below one to eliminate malaria and to gauge the size of
an outbreak arising from an imported malaria case. They
also point out the importance of investigating the sta-
bility of malaria elimination. Bistability of malaria, as we
explore here, is one possible mechanism that could make
malaria elimination more stable. Estimates of our crite-
rion, ρ∗ could be a valuable component of efforts to assess
the stability of malaria control in specific areas.
The details of clinical immunity to malaria are more
complex than those in our simple model: in particular,
clinical immunity continues to develop, there is not sim-
ply one kind of clinical immunity. Nonetheless, we expect
our qualitative results to apply to more realistic situa-
tions. We expect the possibility of bistability when the
relative life-cycle transmission effectiveness of clinically
immune individuals is high. Thus, measuring the com-
ponents of transmission effectiveness, both in clinically
immune and non-immune individuals, is important for
evaluating and planning malaria control efforts. Although
certain aspects of malaria are well studied, it is surpris-
ingly difficult to find information bearing directly on
the components of transmission effectiveness, particularly
in clinically immune individuals. Continued investiga-
tion of how these components determine transmission
effectiveness will be important in understanding the
population-level patterns of the spread and persistence of
malaria.
Although duration of symptomatic infection is well
studied [15,19], little is known about duration of asymp-
tomatic infection [23]. This is a complicated question
because malaria infections can be long and variable; fail-
ure to detect parasites may not mean an infectious event
is over; conversely, parasites that are detected may be due
to a new infectious event.
Transmission of infection to mosquitoes is another
aspect of malaria biology that is not well understood.
Although they are well studied individually, it is not
clear how the components of transmission come together
to affect the infectiousness per transmission event.
These components include: gametocytemia [28,29]; TBI
[30,33,34], which increases with gametocytemia, and
wanes with age and clinical immunity; and other human
and mosquito-specific factors [39]. More information
on how these components interact to affect transmis-
sion would help to unravel how clinical immunity affects
population-level transmission.
As we’ve shown, susceptibility of clinically immune indi-
viduals to malaria is an important component of the ratio
of life-cycle transmission effectiveness. Susceptibility to
new infection is known to be complex [38] but not well
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understood; in the literature “susceptibility” is frequently
used to refer to susceptibility to clinical disease [38,39].
Our model neglects age structure, and oversimplifies
the process of clinical immunity. In particular, the pop-
ulation is divided simply into those who are and are not
clinically immune. Other omissions include seasonality,
biting heterogeneity, and in fact, mosquitoes. For these
reasons, the model is not expected to provide quantita-
tively accurate estimates of malaria dynamics.
The advantage of this simplistic approach, in our opin-
ion, is that the model sheds light on the possible mecha-
nisms and key quantities underlying bistability in malaria
dynamics. In particular, we expect the importance of the
quantity ρ – the ratio of life-cycle effectiveness of trans-
mission between immune and non-immune individuals –
to be robust to including more model details. Similarly,
we expect some analogue of the time scale ratio D/(πL) –
that is, the ratio between the time scales of infection and
immunity – to be important in a detailed model.
Conclusions
It has been suggested that human malaria-transmission
dynamics exhibit bistability, which would have impor-
tant implications for control efforts. We have shown that
bistability through treatment seeking by clinically immune
individuals is plausible in human malaria transmission
dynamics. Using a simple model, we have demonstrated
how these dynamics might play out, and determined
key parameters underlying when and whether bistability
might occur in real populations.
We find that the key quantities underlying whether
bistability is expected to occur are: the relative “effective-
ness” of clinically immune individuals, compared to naïve
individuals, at transmission; and the time scale at which
clinical immunity is lost, compared to the time scale of
infectiousness. The model also shows that relative suscep-
tibility to malaria infection should be considered part of
transmission effectiveness, whenmaking this comparison.
We find that bistability can occur for plausible parameters,
and suggest that more research into these two ratios may
shed light on malaria dynamics, and guide future control
efforts.
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